NEWS

 

Laurent Pharmaceuticals featured in BioCentury Magazine

MONTREAL, QC, Canada – September 15 th, 2015

Laurent Pharmaceuticals Inc. announced today that the LAU-7b program addressing aberrant inflammation is featured in the September 14th issue of BioCentury, one of the most widely read publications in the pharma industry. 

Published under the title “Balancing Act”, the article describes how Laurent Pharmaceuticals thinks its LAU-7b can carve out a niche in CF by correcting the inflammatory imbalance in CF patients and reduce lung deterioration over time, when given on top of standard of care.

Read the article

Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis

MONTREAL, QC, Canada - May 20, 2014
Laurent Pharmaceuticals Inc. announced today that the Research Institute of the McGill University Health Centre (RI-MUHC) has started enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with Cystic Fibrosis (CF) and Pseudomonas aeruginosa lung colonization. The study will be conducted at the Montreal Chest Institute at the MUHC in Montréal, with financial support from McGill University, MSBi Valorisation and Laurent Pharmaceuticals.

Read more ...

A new orphan disease-focused company

MSBi Valorisation announces the creation of Laurent Pharmaceuticals, a new biopharmaceutical company specializing in rare diseases
 
Montreal, QC, Canada – April 22, 2013
MSBi Valorisation (MSBiV), McGill University (McGill) and the Research Institute of the McGill University Health Centre (RI-MUHC) today announced the creation of Laurent Pharmaceuticals, a start-up pharmaceutical company specializing in drug development for orphan diseases. Laurent has a lead program focusing on Fenretinide, an intensively explored but never commercialized synthetic retinoid derivative, as novel therapy for Cystic Fibrosis (CF) patients suffering from lung infection with Pseudomonas aeruginosa.
 

Events

Laurent Pharmaceuticals to participate at NACFC 2019, in Nashville TN, October 31st - November 2nd 2019

Laurent Pharmaceuticals to participate at  BIO2019, in Philadelphia PA, June 3-6 2019